A5039228625- Bipolar Disorder and Treatment
- Electroconvulsive Therapy Studies
- Schizophrenia research and treatment
- Adolescent and Pediatric Healthcare
- Treatment of Major Depression
- Pharmacological Effects and Toxicity Studies
- Child and Adolescent Psychosocial and Emotional Development
- Tryptophan and brain disorders
- Posttraumatic Stress Disorder Research
- Migration, Health and Trauma
- Stuttering Research and Treatment
- Suicide and Self-Harm Studies
- Stress Responses and Cortisol
- Coordination Chemistry and Organometallics
- Attention Deficit Hyperactivity Disorder
- Epilepsy research and treatment
- Mental Health Research Topics
- Electrolyte and hormonal disorders
- Genetics and Neurodevelopmental Disorders
- Family Support in Illness
- Circadian rhythm and melatonin
- Pharmaceutical studies and practices
- Resilience and Mental Health
- Health, Environment, Cognitive Aging
- Mental Health Treatment and Access
University Hospitals of Cleveland
2014-2024
Case Western Reserve University
2015-2024
University School
2011-2024
Yale University
2007-2022
Dalhousie University
2000-2022
University of Iowa
2022
University of California, San Diego
2022
University of Michigan
2009-2022
Salk Institute for Biological Studies
2022
California University of Pennsylvania
2022
Bipolar spectrum disorders, which include bipolar I, II, and disorder not otherwise specified, frequently go unrecognized, undiagnosed, untreated. This report describes the validation of a new brief self-report screening instrument for disorders called Mood Disorder Questionnaire.A total 198 patients attending five outpatient clinics that primarily treat with mood completed Questionnaire. A research professional, blind to Questionnaire results, conducted telephone diagnostic interview by...
The Canadian Network for Mood and Anxiety Treatments (CANMAT) previously published treatment guidelines bipolar disorder in 2005, along with international commentaries subsequent updates 2007, 2009, 2013. last two were collaboration the International Society Bipolar Disorders (ISBD). These 2018 CANMAT ISBD Treatment Guidelines represent significant advances field since full edition was including to diagnosis management as well new research into pharmacological psychological treatments. have...
Article AbstractBackground: More treatment options for bipolar depression are needed. Currently available antidepressants may increase the risk of mania and rapid cycling, mood stabilizers appear to be less effective in treating than mania. Preliminary data suggest that lamotrigine, an established antiepileptic drug, both associated with disorder. This is first controlled multicenter study evaluating lamotrigine monotherapy I depression. Method: Outpatients disorder experiencing a major...
Episodes of depression are the most frequent cause disability among patients with bipolar disorder. The effectiveness and safety standard antidepressant agents for depressive episodes associated disorder (bipolar depression) have not been well studied. Our study was designed to determine whether adjunctive therapy reduces symptoms without increasing risk mania.
Background: Despite the longer duration of depressive phase in bipolar disorder and frequent clinical use antidepressants combined with antipsychotics or mood stabilizers, relatively few controlled studies have examined treatment strategies for depression.Objective: To examine olanzapine olanzapine-fluoxetine combination I depression.Design: Double-blind, 8-week, randomized trial.Setting: Eighty-four sites (inpatient outpatient) 13 countries.Patients: A total 833 adults depression a...
There is a major unmet need for effective options in the treatment of bipolar depression.Five hundred forty-two outpatients with I (N=360) or II (N=182) disorder experiencing depressive episode (DSM-IV) were randomly assigned to 8 weeks quetiapine (600 300 mg/day) placebo. The primary efficacy measure was mean change from baseline week Montgomery-Asberg Depression Rating Scale total score. Additional assessments included Hamilton Scale, Clinical Global Impression severity and improvement,...
Primary depression can be associated with substantial hypercortisolism, thus prompting some researchers to suggest that shares pathophysiologic features Cushing's disease. Clinically, difficult or impossible distinguish from mild early disease is depressive features. The purpose of this study was evaluate whether the pituitary-adrenal responses ovine corticotropin-releasing hormone could help clarify mechanism hypercortisolism in and assist differential diagnosis these disorders. As compared...
The risk-benefit profile of antidepressant medications in bipolar disorder is controversial. When conclusive evidence lacking, expert consensus can guide treatment decisions. International Society for Bipolar Disorders (ISBD) convened a task force to seek recommendations on the use antidepressants disorders.An iteratively developed through serial consensus-based revisions using Delphi method. Initial survey items were based systematic review literature. Subsequent surveys included new or...
<h3>Background</h3> Long-term outcomes are often poor in patients with bipolar disorder despite treatment; more effective treatments needed to reduce recurrences and morbidity. This study compared the efficacy of divalproex, lithium, placebo as prophylactic therapy. <h3>Methods</h3> A randomized, double-blind, parallel-group multicenter treatment was conducted over a 52-week maintenance period. Patients who met recovery criteria within 3 months onset an index manic episode (n=372) were...
Article Abstract Background: Our goal was to estimate the rate of positive screens for bipolar I and II disorders in general population United States. Method: The Mood Disorder Questionnaire (MDQ), a validated screening instrument disorders, sent sample 127,800 people selected represent U.S. adult by demographic variables. 85,358 subjects (66.8% response rate) that were 18 years age or above returned survey had usable data. Of nonrespondents, 3404 matched demographically 2000 Census data...
Article Abstract Background: The anticonvulsant lamotrigine was previously shown to be effective for bipolar depression. This study assessed the efficacy and tolerability of lithium compared with placebo prevention mood episodes in disorder. Method: During an 8- 16-week open-label phase, (titrated 200 mg/day) added current therapy currently or recently depressed DSM-IV-defined I outpatients (N = 966) concomitant drugs were gradually withdrawn. Patients stabilized on treatment 463) then...
Article AbstractBackground: Two clinical trials, prospectively designed for combined analysis, compared placebo, lithium, and lamotrigine treatment of bipolar I disorder in recently depressed or manic patients. Method: 1315 patients (DSM-IV) enrolled the initial open-label phase, 638 were stabilized randomly assigned to 18 months double-blind monotherapy with (N = 280; 50-400 mg/day fixed dose 100-400 flexible dose), lithium 167; serum level 0.8-1.1 mEq/L), placebo 191). The primary endpoint...
The Canadian Network for Mood and Anxiety Treatments (CANMAT) published guidelines the management of bipolar disorder in 2005, with a 2007 update. This second update, conjunction International Society Bipolar Disorders (ISBD), reviews new evidence is designed to be used previous publications. recommendations acute mania remain mostly unchanged. Lithium, valproate, several atypical antipsychotics continue first‐line treatments mania. Tamoxifen now suggested as third‐line augmentation option....
This study evaluated the efficacy and tolerability of quetiapine monotherapy for depressive episodes in patients with bipolar I or II disorder (Diagnostic Statistical Manual Mental Disorders, Fourth Edition) who were randomized to 8 weeks double-blind treatment (300 600 mg/d; once daily, evening dosing) placebo. Patients assessed weekly using Montgomery-Asberg Depression Rating Scale (MADRS) Hamilton (HAM-D). The primary end point was change MADRS total score from baseline Week (analysis...
Context: Psychosocial interventions have been shown to enhance pharmacotherapy outcomes in bipolar disorder.Objective: To examine the benefits of 4 disorderspecific psychotherapies conjunction with on time recovery and likelihood remaining well after an episode depression.Design: Randomized controlled trial.Setting: Fifteen clinics affiliated Systematic Treatment Enhancement Program for Bipolar Disorder.Patients: A total 293 referred outpatients I or II disorder depression treated protocol...
Article AbstractBackground: Patients with rapid-cycling bipolardisorder are often treatment refractory. This study examinedlamotrigine as maintenance monotherapy for bipolardisorder. Method: Lamotrigine was added to patients'current psychotropic regimens and titrated clinical effectduring an open-label phase. Stabilized patients weretapered off other psychotropics randomly assigned tolamotrigine or placebo 6 months. Time toadditional pharmacotherapy emerging symptoms the primaryoutcome...
<h3>Background</h3> A 6-week double-blind, randomized, placebo-controlled trial was conducted to determine the efficacy of combined therapy with olanzapine and either valproate or lithium compared alone in treating acute manic mixed bipolar episodes. <h3>Methods</h3> The primary objective evaluate (5-20 mg/d) vs placebo when added ongoing mood-stabilizer as measured by reductions Young Mania Rating Scale (YMRS) scores. Patients disorder (n = 344), episode, who were inadequately responsive...